Ipsen S.A. (EPA:IPN)

Market Cap	12.18B +34.4%
Revenue (ttm)	3.93B +9.9%
Net Income	443.50M +28.2%
EPS	5.32 +28.2%
Shares Out	82.10M
PE Ratio	27.89
Forward PE	11.47
Dividend	1.40 (0.94%)
Ex-Dividend Date	Jun 4, 2025

Volume	82,126
Average Volume	120,436
Open	148.60
Previous Close	148.40
Day's Range	147.50 - 150.20
52-Week Range	87.95 - 167.10
Beta	0.34
RSI	43.55
Earnings Date	Apr 23, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 5,535
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPN

Financial Performance

In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.